Sriram Tyagarajan

This inventor holds 10 USPTO granted patents and 3 published patent applications and 5 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc.. Active years: 2003-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sriram Tyagarajan. Retrieved from https://idiyas.com/inventor/sriram-tyagarajan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 3)

% Patents Active = 70.0

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 9.3

ph-index = 3

Forward Citations = 27(Granted Patents)

Company Filing History:

7 out of 2,405

Merck Sharp + Dohme Corp.

Years Active: 2003-2021

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10934294 - Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors (2021-03-02),

2. 10730849 - Benzo[b]thiophene compounds as STING agonists (2020-08-04),

3. 10703738 - Benzo[b]thiophene compounds as STING agonists (2020-07-07),

4. 10414747 - Benzo[b]thiophene compounds as sting agonists (2019-09-17),

5. 9717714 - Spirocyclic CETP inhibitors (2017-08-01),

6. 8742110 - Spiroxazolidinone compounds (2014-06-03),

7. 8304434 - Substituted aryl sulfone derivatives as calcium channel blockers (2012-11-06),

8. 7589116 - Biaryl substituted pyrazoles as sodium channel blockers (2009-09-15),

9. 7348348 - Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers (2008-03-25),

10. 6586452 - C1 to C4 side chain modified nodulisporic acid analogs (2003-07-01),

Title: Innovator Sriram Tyagarajan: Advancing Therapeutics through Innovative Patents

Introduction

Sriram Tyagarajan, based in Edison, NJ, is a notable inventor recognized for his contributions to pharmaceutical advancements. With a remarkable portfolio of 10 patents, he is dedicated to developing innovative therapeutic agents aimed at tackling a range of health challenges.

Latest Patents

Among his latest inventions, Tyagarajan has developed substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors. This invention focuses on pyrazolopyrimidine compounds that offer potential therapeutic benefits for disorders linked to phosphodiesterase 9 (PDE9). These compounds are designed to treat cardiovascular diseases such as hypertension, chronic kidney disease, and heart failure, in addition to various neurological and psychiatric disorders including schizophrenia, psychosis, and Huntington's disease.

Another significant patent involves benzo[b]thiophene compounds functioning as STING agonists. These compounds aim to induce type I interferon production, showcasing their potential as STING active agents. The patent also details the synthesis processes and applications of these compounds in therapeutic contexts.

Career Highlights

Throughout his career, Sriram Tyagarajan has contributed significantly to the field of pharmaceuticals, particularly while working with prestigious organizations like Merck Sharp & Dohme Corporation and Merck & Company, Inc. His experience in these leading companies has been pivotal in shaping his innovative approach toward drug discovery and development.

Collaborations

Sriram Tyagarajan has worked alongside distinguished colleagues such as Prasun K Chakravarty and Michael D Altman. Their collaborative efforts have enhanced the research outcomes and efficiency in bringing innovative pharmaceutical solutions to fruition.

Conclusion

Sriram Tyagarajan's inventive spirit has paved the way for significant advancements in therapeutic agents aimed at serious health conditions. His dedication and innovative work are evident in his numerous patents, reinforcing his role as a key contributor to the field of pharmaceuticals.

Profile summary based on public USPTO records.